The Non-Responder Mystery
A leading diabetologist, Dr. Anoop Misra, encountered a perplexing case with a 30-year-old patient undergoing treatment for obesity. Despite two months
of using a weight-loss injectable and even a dosage increase, the expected weight loss was not materializing. Initially, Dr. Misra attributed the lack of results to individual patient response, but the patient’s growing concern about potential fake drugs from a specific pharmacy sparked doubt. This anomaly was the first of its kind in Dr. Misra’s experience, prompting him to investigate further.
A Shocking Discovery
Dr. Misra’s concerns were amplified when news broke about the seizure of counterfeit Mounjaro KwikPens, valued at Rs 56 lakh, in Gurugram, exposing a significant illegal drug manufacturing and distribution network. This event made him recall a similar, earlier concern voiced by another patient in Gurugram, which he had dismissed due to confidence in the drug's international manufacturing standards. The stark reality of the counterfeit drug bust eroded his certainty, making it challenging to reassure his patients about the authenticity of their medication.
The Call for Clarity
In light of these developments, Dr. Misra has formally requested regulatory bodies, including the Central Drugs Standard Control Organisation (CDSCO), to issue comprehensive guidance on how to identify genuine batches of tirzepatide. He emphasizes that without such clear directives, both prescribing physicians and patients are left vulnerable to potentially harmful counterfeit supplies. Dr. Misra believes an official advisory detailing packaging features, pen device specifics, and supply chain verification methods is crucial to ensure patients receive the intended therapeutic benefits without compromising their health.
Why Guidance Matters
Dr. Misra asserts that the absence of an official advisory forces doctors to rely on unreliable sources like unverified social media content and videos for authentication. He argues that a clear, government-issued advisory would empower clinicians to identify genuine drugs themselves, and subsequently guide pharmacists and patients on verification. This clarity is especially vital given the high cost of these medications and the inherent dangers associated with counterfeit products. While the CDSCO has provided advisories on authorized prescribers, a focused guide on product authenticity is deemed essential for public safety.
Detection Challenges
Identifying counterfeit weight-loss drugs is a significant challenge, even for medical professionals, as fake products can be visually indistinguishable from authentic ones, according to Dr. Ravindra Goswami, a Professor of Endocrinology at AIIMS Delhi. He notes that past instances involved refilling discarded bottles, making detection extremely difficult. Therefore, simply providing visual identification guidelines might not be sufficient. The focus, he stresses, should be on robust enforcement, tracing supply chains, dismantling criminal operations, and imposing severe penalties to deter such activities.
The Cold Chain Imperative
Dr. Goswami also highlights the critical importance of maintaining the cold chain for injectable medications like tirzepatide. These drugs are temperature-sensitive and require strict storage between 2°C and 8°C. Any disruption in the supply chain, from transport to storage and even post-purchase, can degrade the active compound, rendering the medication ineffective without any visible alteration. This invisible degradation makes it particularly challenging to identify compromised products, as the pen may appear normal and the liquid clear.
Patient Impact
The consequences for patients using counterfeit or degraded drugs can be severe. Fake products might contain no active ingredient or harmful contaminants. Patients may experience poor weight loss, unstable blood sugar, or unexpected side effects, while mistakenly believing they are receiving effective treatment. This can lead to the unchecked progression of obesity-related complications like diabetes and hypertension. Additionally, incorrect formulations or adulterants can trigger dangerous adverse reactions, including severe nausea, vomiting, dehydration, allergic responses, pancreatitis, and kidney issues. Furthermore, patients might delay seeking medical help, losing valuable treatment time due to the gradual nature of the drug's effects.
Identifying Genuine Cases
Distinguishing between a genuine non-response to medication and the use of a counterfeit drug can be complicated. Dr. Goswami points out that the incidence of true non-responders is generally very low. Factors like poor individual response or drug resistance can mimic the outcomes seen with fake medicines, making it difficult to rely solely on therapeutic results for identification. This complexity underscores the need for definitive methods to verify drug authenticity, beyond just observing treatment outcomes.
